BioNTech: Advancing science to help transform cancer and ...
BioNTech develops mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies in oncology, and vaccines against infectious diseases.
BioNTech - Wikipedia
BioNTech SE (/ biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that …
Welcome to our investor page | BioNTech
Dec 18, 2025 · Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and …
BioNTech SE (BNTX) - Yahoo Finance
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including...
FDA Fast Track Win And New HR Chief Might Change The Case For ...
5 days ago · Earlier this month, research firm Leerink Partners downgraded BioNTech SE’s rating after a strong rally, even as the company secured FDA Fast Track designation for its cancer candidate …
BNTX Stock Price | BioNTech SE ADR Stock Quote ... - MarketWatch
Feb 17, 2026 · BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, …
BioNTech SE | Reuters
Dec 29, 2025 · The latest international BioNTech SE news and views from Reuters - one of the world's largest news agencies